Mbx Biosciences, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
MBX Biosciences, Inc. reported significant progress in its clinical pipeline, including positive Phase 2 results for canvuparatide in hypoparathyroidism and advancement of obesity and post-bariatric hypoglycemia candidates, alongside increased net losses and a strong cash position to fund operations into 2029.
NASDAQ
MBX Biosciences' 10-K filing summarizes the company's financial performance for 2024 and provides updates on its clinical-stage precision peptide therapies for endocrine and metabolic disorders.